Look­ing to get ahead in a packed mi­graine mar­ket, Am­gen touts head-to-head da­ta for Aimovig

A year af­ter Am­gen an­nounced its in­jectable mi­graine pre­ven­tion drug Aimovig proved a bet­ter op­tion than the wide­ly used treat­ment top­i­ra­mate in a head-to-head study, the phar­ma com­pa­ny is rolling out the full da­ta. But will it be enough to com­pete in a packed mar­ket, in­clud­ing new oral op­tions?

In a Phase IV study con­duct­ed by Am­gen’s old part­ner No­var­tis, mi­graine pa­tients in the Aimovig arm showed a sig­nif­i­cant­ly low­er dis­con­tin­u­a­tion rate due to side ef­fects: 10.5% ver­sus 38.9% in the top­i­ra­mate arm (p<0.001), ac­cord­ing to the com­pa­nies. In ad­di­tion, 55.4% of pa­tients in the Aimovig arm achieved at least a 50% re­duc­tion from base­line in their month­ly mi­graine days, com­pared to 31.2% in the top­i­ra­mate group (p<0.001).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER